4th Quarter - Termination — LIFE TECHNOLOGIES CORPORATION for LIFE TECHNOLOGIES CORPORATION (2013)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

LIFE TECHNOLOGIES CORPORATION

Client

LIFE TECHNOLOGIES CORPORATION

Income

—

Expenses

$50,000

Expense method

A: Lobbying Disclosure Act definitions

Terminated

Dec 31, 2013

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
4th Quarter - Termination (this page)	Jan 15, 2014	$50,000	Replaced
4th Quarter - Termination Amendment	Apr 23, 2014	$50,000	Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

H.R. 3309: The Innovation Act; Provisions regarding patent litigation reform.

Lobbyist	Covered position, as disclosed
JANET LYNCH LAMBERT	N/A

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 3309 (113th)

Medicare/Medicaid MMM

Subregulatory: Molecular Pathology Fee Schedules; Provisions regarding Medicare rate settings for certain diagnostics. S. 1871: The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013; Provisions regarding diagnostic amendments.

Lobbyist	Covered position, as disclosed
AMY MUHLBERG	N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1871 (113th)

Budget/Appropriations BUD

Departments of Labor, Health and Human Services and Education, and Related Agencies Appropriations Act, FY 2014; Provisions regarding National Institutes of Health funding.

Lobbyist	Covered position, as disclosed
JANET LYNCH LAMBERT	N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Medical/Disease Research/Clinical Labs MED

H.R. 3005: Medical Testing Availablity Act of 2013; Provisions regarding FDA regulations of certain diagnostics and lab developed tests. Draft and final guidance regarding commercially distributed in vitro diagnostic products labeled "For Research Only" or "Investigational Use Only"; Provisions regarding FDA regulation of certain diagnostics.H.R. 2085: Diagnostic Innovation Testing and Knowledge Advancement Act of 2013; Provisions regarding value based payment for advanced diagnostics.

Lobbyist	Covered position, as disclosed
JANET LYNCH LAMBERT	N/A
AMY MUHLBERG	N/A

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3005 (113th), H.R. 2085 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.